Skip to content

Study · Randomized controlled trial · n = 24 · 2003

3 results

Effect of propranolol and depot lanreotide SR on postprandial and circadian portal haemodynamics in cirrhosis.

Schiedermaier P, Koch L, Stoffel-Wagner B, Layer G, Sauerbruch T

Alimentary pharmacology & therapeutics1 Oct 2003Cited by 8 (Europe PMC)

PMID14535870 (opens in a new tab)DOI10.1046/j.1365-2036.2003.01682.x (opens in a new tab)PepBankPUB-14535870
Source linkPubMedAsk about this study
Jump to 3 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study3

3 results from studies that gave the peptide. 3 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In cirrhosis, lanreotide reduced baseline HVPG less than propranolol (-13.6% versus -21.9%, P=0.04).

    In plain wordsIn cirrhosis, lanreotide reduced baseline portal pressure less than propranolol.

    Peptide
    Lanreotide
    Outcome
    IncreaseBaseline HVPG
    Study

    n = 24

    Comparator
    propranolol
    Outcome group
    Blood pressure · Liver
    Studied dose
    30 mg once weekly · intramuscular · 3 weeksAs given in this study (human).

    Measurements

    change in baseline HVPG
    −13.6%
    lanreotide SR 30 mg weekly
    change in baseline HVPG
    −21.9%
    propranolol

    Source sentences

    Summary
    Propranolol was more effective than lanreotide SR in reducing baseline HVPG (-21.9 vs. -13.6%, P=0.04) and meal-stimulated HVPG (-16.6 vs. -3.8%, P=0.04).
    2 context sentences
    Summary · context
    Patients were randomized to receive either lanreotide SR intramuscularly (30 mg once weekly, n=12) or propranolol (n=12) orally.
    Summary · context
    Hemodynamic measurements were performed on day 0 and on day 21 after a 3-week period of drug administration, while patients received three standard oral liquid test meals.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In cirrhosis, lanreotide reduced meal-stimulated HVPG less than propranolol (-3.8% versus -16.6%, P=0.04).

    In plain wordsIn cirrhosis, lanreotide reduced meal-stimulated portal pressure less than propranolol.

    Peptide
    Lanreotide
    Outcome
    IncreaseMeal-stimulated HVPG
    Study

    n = 24

    Comparator
    propranolol
    Outcome group
    Blood pressure · Liver
    Studied dose
    30 mg once weekly · intramuscular · 3 weeksAs given in this study (human).

    Measurements

    change in meal-stimulated HVPG
    −3.8%
    lanreotide SR 30 mg weekly
    change in meal-stimulated HVPG
    −16.6%
    propranolol

    Source sentences

    Summary
    Propranolol was more effective than lanreotide SR in reducing baseline HVPG (-21.9 vs. -13.6%, P=0.04) and meal-stimulated HVPG (-16.6 vs. -3.8%, P=0.04).
    2 context sentences
    Summary · context
    Patients were randomized to receive either lanreotide SR intramuscularly (30 mg once weekly, n=12) or propranolol (n=12) orally.
    Summary · context
    Hemodynamic measurements were performed on day 0 and on day 21 after a 3-week period of drug administration, while patients received three standard oral liquid test meals.
  3. 03HumanNon-randomized trialEfficacy outcome

    In cirrhosis, lanreotide did not significantly reduce circadian portal blood flow.

    In plain wordsIn cirrhosis, lanreotide did not significantly reduce daily portal blood flow.

    Peptide
    Lanreotide
    Outcome
    No significant changeCircadian portal blood flow
    Study

    n = 12

    Outcome group
    Blood pressure · Liver
    Studied dose
    30 mg once weekly · intramuscular · 3 weeksAs given in this study (human).

    Source sentences

    Summary
    Propranolol reduced circadian PVF significantly by 9.3% (P=0.03) but not lanreotide SR.
    2 context sentences
    Summary · context
    Patients were randomized to receive either lanreotide SR intramuscularly (30 mg once weekly, n=12) or propranolol (n=12) orally.
    Summary · context
    Hemodynamic measurements were performed on day 0 and on day 21 after a 3-week period of drug administration, while patients received three standard oral liquid test meals.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.